Coya Therapeutics presents COYA 302 ALS trial update, expects data in early Q2 2027
COYA•Coya Therapeutics expects topline results from its fully enrolled, 137-patient Phase 2/3 ALS trial of COYA 302 in early Q2 2027. It reported $35.8 million in cash as of September 30, 2026, and expects a frontotemporal dementia trial to begin in 2027.
1. ALS trial update
Coya Therapeutics expects topline results from its fully enrolled, 137-patient ALSTARS Phase 2/3 trial of COYA 302 in ALS in early Q2 2027. The company reported $35.8 million in cash as of September 30, 2026, which it said supports operations into the second half of 2027, beyond the expected ALS readout.
2. Other programs
A Phase 2 trial of COYA 302 in frontotemporal dementia is expected to begin in 2027. The company said its ALS partnership with Dr. Reddy's provides up to approximately $700 million in potential milestones, plus royalties on net sales; development of COYA 303 in Alzheimer's disease depends on securing non-dilutive funding or a partnership.
